[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100591414":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":19,"locations":25,"responsibleParty":109,"collaborators":11,"id":111,"slug":112,"hasResults":113,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":11,"eligibilityCriteria":117,"healthyVolunteers":113,"sex":118,"minAge":119,"maxAge":11,"enrollmentInfo":120,"targetDuration":11,"studyType":123,"phases":124,"briefSummary":126,"conditions":127,"keywords":135,"overallStatus":28,"whyStopped":11,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":149},{"fullName":5,"class":6},"Exscientia AI Limited","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"EXS73565","EXPERIMENTAL",null,[13],"Drug: EXS73565",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"DRUG","EXS73565 oral administration",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":11,"email":24},"Exscientia AI Ltd.","CONTACT","385-374-1724","clinicaltrials@recursion.com",[26,39,50,61,66,71,80,91,101],{"facility":27,"status":28,"city":29,"state":11,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":11},"LLC ARENSIA Exploratory Medicine","RECRUITING","Tbilisi","119","Georgia","GE",{"type":34,"coordinates":35},"Point",[36,37],44.83412,41.69143,{"lat":37,"lon":36},{"facility":40,"status":28,"city":41,"state":11,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":49,"contacts":11},"IMSP Institute of Oncology, ARENSIA Exploratory Medicine","Chisinau","MD-2025","Moldova","MD",{"type":34,"coordinates":46},[47,48],28.85938,47.00902,{"lat":48,"lon":47},{"facility":51,"status":28,"city":52,"state":11,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":60,"contacts":11},"Hospital Beata Maria Ana","Madrid","28007","Spain","ES",{"type":34,"coordinates":57},[58,59],-3.70256,40.4165,{"lat":59,"lon":58},{"facility":62,"status":28,"city":52,"state":11,"zip":11,"country":54,"countryCode":55,"cosmosGeoPoint":63,"geoPoint":65,"contacts":11},"Hospital Fundación Jiménez Diaz",{"type":34,"coordinates":64},[58,59],{"lat":59,"lon":58},{"facility":67,"status":28,"city":52,"state":11,"zip":11,"country":54,"countryCode":55,"cosmosGeoPoint":68,"geoPoint":70,"contacts":11},"Hospital Universitario HM Sanchinarro",{"type":34,"coordinates":69},[58,59],{"lat":59,"lon":58},{"facility":72,"status":28,"city":73,"state":11,"zip":74,"country":54,"countryCode":55,"cosmosGeoPoint":75,"geoPoint":79,"contacts":11},"Clinica Universidad de Navarra","Pamplona","31008",{"type":34,"coordinates":76},[77,78],-1.64323,42.81687,{"lat":78,"lon":77},{"facility":81,"status":28,"city":82,"state":11,"zip":83,"country":84,"countryCode":85,"cosmosGeoPoint":86,"geoPoint":90,"contacts":11},"Medical Center of LLC ARENSIA Exploratory Medicine","Kyiv","01135","Ukraine","UA",{"type":34,"coordinates":87},[88,89],30.5238,50.45466,{"lat":89,"lon":88},{"facility":92,"status":28,"city":93,"state":11,"zip":11,"country":94,"countryCode":95,"cosmosGeoPoint":96,"geoPoint":100,"contacts":11},"St James's University Hospital","Leeds","United Kingdom","UK",{"type":34,"coordinates":97},[98,99],-1.54785,53.79648,{"lat":99,"lon":98},{"facility":102,"status":28,"city":103,"state":11,"zip":11,"country":94,"countryCode":95,"cosmosGeoPoint":104,"geoPoint":108,"contacts":11},"University Hospitals Plymouth NHS Trust (Derriford Hospital)","Plymouth",{"type":34,"coordinates":105},[106,107],-4.14305,50.37153,{"lat":107,"lon":106},{"type":110,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100591414","phase-1-dose-determining-study-of-exs73565-in-participants-with-relapsed-or-refractory-b-cell-malignancies-100591414",false,"NCT06980116","Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies","A Phase 1 Open-label, Multicenter, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of EXS73565 in Participants With Relapsed or Refractory B-cell Malignancies","Key Inclusion Criteria:\n\n* Age ≥18 years at the time of signing the informed consent.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* Histologically confirmed diagnosis of one of the following B-cell malignancies: chronic lymphocytic leukemia (CLL), including Richter's transformation from CLL, mantle-cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, or waldenström macroglobulinaemia.\n* Participants that have relapsed after standard of care or have progressed during standard of care or are not suitable for standard of care therapy\n\nKey Exclusion Criteria:\n\n* Any medical or psychiatric condition that, in the view of the Principal Investigator, could jeopardize or would compromise the participant's safety or ability to participate in the study.\n* Known central nervous system (CNS) malignancy or primary CNS lymphoma.\n* Concurrent active or previous malignancy (other than the primary lymphoma\u002FCLL for which the participant will be treated on this protocol within 5 years prior to randomization; participants with prior cancers may be enrolled with documented Sponsor approval.\n* Received anticancer therapy, including chemotherapy, immunotherapy, radiation therapy (with the exception of palliative radiotherapy), biologic therapy, cancer-related hormonal therapy, or any investigational therapy within 14 days or 5 half-lives (whichever is shorter) before the first dose of the study treatment.","ALL","18 Years",{"count":121,"type":122},85,"ESTIMATED","INTERVENTIONAL",[125],"PHASE1","The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of EXS73565 administered orally as a single agent in participants with relapsed\u002Frefractory B-cell malignancies.",[128,129,130,131,132,133,134],"Relapsed or Refractory B-cell Malignancies","Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma (CLL\u002FSLL)","Follicular Lymphoma (FL)","Marginal Zone Lymphoma (MZL)","Mantle Cell Lymphoma (MCL)","Diffuse-large B-cell Lymphoma (DLBCL)","Waldenstrom's Macroglobulinemia (WM)",[136,137,130,131,132,133,134,138],"B-cell Malignancies","Chronic lymphocytic leukemia\u002Fsmall lymphocytic lymphoma (CLL\u002FSLL)","MALT1","2026-06-09",{"date":141,"type":142},"2026-06-11","ACTUAL",{"date":144,"type":142},"2025-03-31",{"date":146,"type":122},"2028-12",{"name":148,"class":6},"Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.",9]